PbsNRs: predict the potential binders and scaffolds for nuclear receptors

Genhui Zheng, Dingfeng Wu, Xiuxia Wei, Dongpo Xu, Tiantian Mao, Deyu Yan, Wenhao Han, Xiaoxiao Shang, Zikun Chen, Jingxuan Qiu, Kailin Tang, Zhiwei Cao, Tianyi QiuBriefings in Bioinformatics 2025 · DOI

TL;DR

Researchers have developed PbsNRs, a user-friendly web server that uses proteochemometric modeling to predict potential drug binders and molecular scaffolds for nuclear receptors (NRs). This tool outperforms existing methods and has been experimentally validated, offering a promising avenue for accelerating the discovery of new NR-targeted therapies for various diseases.

What Problem Does This Paper Address?

Nuclear receptors (NRs) are crucial protein targets for drug development, involved in a wide range of physiological processes and implicated in numerous diseases, including cancer, diabetes, and liver disorders. While a significant percentage of approved drugs target NRs, the process of identifying effective NR binders and novel molecular scaffolds is challenging and time-consuming. Existing computational methods for predicting drug-target interactions often focus on individual protein-ligand pairs or have limited scope, failing to adequately address the specific needs of NR drug discovery. There's a clear need for a more comprehensive and accurate in silico tool that can efficiently prescreen potential binders and identify promising molecular scaffolds for the diverse family of NRs.

Methods

The core of PbsNRs is a proteochemometric modeling (PCM) approach. Unlike traditional quantitative structure-activity relationship (QSAR) models that focus solely on chemical compound properties, PCM integrates information from both the ligand (chemical compound) and the target protein (NR).

Here's a breakdown of their methodology:

  • Descriptor Generation:
    • Ligands: Chemical and physical properties of small molecules are described using RDKit, generating 187-dimensional descriptors.
  • Proteins (NRs): For each NR target, a 30-dimensional descriptor is created by calculating its similarity to 30 "background" NRs (those with available crystal structures in the PDB) using the Smith-Waterman alignment algorithm. This allows the model to leverage information from NRs with known structures and bioactivity data to predict for NRs that lack such data.
  • Machine Learning Models:
    • Random Forest (RF): This ensemble learning method was chosen for its robustness and good performance on tabular data.
  • Deep Learning (DL): A backpropagation neural network was also explored for comparison.
  • Model Training and Optimization:
    • The model was trained using a dataset of 6554 bioactive compounds with known EC50 values against five NR targets.
  • To address the imbalance between positive and negative samples in the training data, oversampling techniques were employed.
  • Gaussian noise was added to enhance model robustness.
  • Extensive parameter optimization was performed, including varying training set percentages and oversampling numbers.
  • Web Server and Python Package: A user-friendly web server (http://pbsnrs.badd-cao.net) and a downloadable Python package were developed to make PbsNRs accessible to the research community.

Datasets

  • Training and Internal Validation: The Orphan Nuclear Receptor Ligand Binding Database (ONRLDB) [51] was used, containing 6554 bioactive compounds with corresponding EC50 values against five NR targets.
  • External Validation: 713 independent bioactive compounds for six other NRs not included in the initial modeling dataset were used to evaluate the model's generalization ability.
  • Screening Databases:
    • ChEMBL [45] (5000 randomly selected chemical structures)
    • DrugBank [46] (FDA-approved and experimental drugs)
    • TCM@Taiwan [52] (natural products)
    • Herbal Ingredients' Targets Database (HIT 2.0) [53] and Natural Product Activity and Species Source (NPASS) [54] were used for screening natural products for NR2B1 ligands.

Key Insights and Ideas

  • Proteochemometric Modeling for NRs is Powerful: Integrating both ligand and protein features (PCM) significantly improves prediction accuracy for NR-ligand interactions compared to methods that only consider one aspect. This is a key differentiator for PbsNRs.
  • Natural Products are Promising NR Ligand Sources: The study found that natural products from the TCM@Taiwan database showed a significantly higher proportion of potential NR binders compared to FDA-approved drugs and experimental compounds. This highlights natural products as a valuable resource for NR drug discovery.
  • Scaffold Identification is Possible: PbsNRs not only predicts binders but also helps identify recurring molecular scaffolds within bioactive compound clusters, which can guide the design of new drug candidates.
  • RF Outperforms Deep Learning for this Task: For this specific problem with tabular data (molecular fingerprints), the Random Forest classifier demonstrated better robustness and generalization ability than deep learning models, especially on external validation sets.
  • Transfer Learning is Effective: By using similarity to known NR structures, PbsNRs can extend its predictive capabilities to NRs for which experimental bioactivity data is scarce.

Key Results

  • High Prediction Accuracy:
    • Internal Validation: PbsNRs achieved an ROC-AUC of 0.906 using the RF classifier.
  • External Validation: PbsNRs achieved an ROC-AUC of 0.783 using the RF classifier, outperforming other state-of-the-art tools.
  • Superior Performance: PbsNRs significantly outperformed existing compound-protein interaction (CPI) prediction tools (Tsubaki's model, DeepCPI) and NR-specific predictors (NR-ToxPred, NR-Profiler) on external validation datasets.
  • Experimental Validation: Seven predicted NR2B1 ligands from natural product databases were experimentally tested using biosensors. The results showed 100% agreement between PbsNRs' in silico predictions and experimental outcomes.
  • Speed Advantage: PbsNRs was at least 400-1100 times faster than popular docking approaches (AutoDock, CDDOCKER, LibDOCK) for virtual screening tasks.
  • Broad Application: PbsNRs successfully screened large databases of chemical compounds and natural products, identifying potential binders and scaffolds.

Limitations and Future Work

  • Scaffold Similarity Limitations: The authors acknowledge that PbsNRs might provide similar predictions for compounds with very similar scaffolds, which could sometimes lead to opposite bioactivities.
  • Future Directions:
    • Incorporate 3D Descriptors: Future work could involve adding 3D descriptors to capture more precise molecular information, especially as more NR structures become available.
  • Describe Functional Groups: Beyond scaffolds, incorporating descriptions of specific functional groups could enhance screening accuracy.
  • Expand NR Coverage: Continuously updating the NR library and incorporating more bioactivity data will further improve the model's performance and scope.

Summary updated

BibTeX
@article{zheng2025pbsnrs,
  author = {Genhui Zheng and Dingfeng Wu and Xiuxia Wei and Dongpo Xu and Tiantian Mao and Deyu Yan and Wenhao Han and Xiaoxiao Shang and Zikun Chen and Jingxuan Qiu and Kailin Tang and Zhiwei Cao and Tianyi Qiu},
  title = {{PbsNRs: predict the potential binders and scaffolds for nuclear receptors}},
  journal = {Briefings in Bioinformatics},
  year = {2025},
  doi = {10.1093/bib/bbae710},
}
Figure